iPSC technology for dry AMD disease models: ➡ Our friends at Phenocell have been working on iPSC-derived models for age-related macular degeneration (AMD), the leading cause of blindness in the elderly population that currently affects over 200 million people worldwide. ➡ AMD can be characterized as “wet” (exudative) or “dry” (non-exudative), with the dry form accounting for around 90% of all cases. Despite this, there are currently no therapies for dry AMD and so, with rates expected to increase by 44% by 2040, there is a pressing need to develop human-relevant models to unlock insights and drive new therapies Phenocell are tackling this with iPSC products and services geared towards human-relevant dry AMD models. They have performed extensive characterization and validation of the key cell type (retinal pigment epithelium, RPE) and have developed a range of assays for dry AMD research. Check out their document below - #amd #ipsc #drugscreening
Want to know more about our iPSC-RPE cell-based drug screening platform for AMD ? Contact us !